Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

  • In development
  • GID-TA10900
  • Expected publication date: TBC
Following conversations with the company, the timelines for this appraisal are now to be confirmed. New timelines will be shared in November 2022.